Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals Ownership Summary

Zentalis Pharmaceuticals is owned by 12.84% institutional investors, 22.44% insiders, and 64.72% retail investors. Blackrock is the largest institutional shareholder, holding 6.80% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.

ZNTL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Zentalis Pharmaceuticals	12.84%	22.44%	64.72%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	4.82M	6.80%	$19.71M
5am venture management	3.95M	5.51%	$9.24M
Two sigma investments, lp	2.96M	4.13%	$6.92M
Acadian asset management	2.85M	3.97%	$6.66M
Vanguard group	2.86M	3.96%	$3.86M
Renaissance	1.94M	2.70%	$4.54M
Citadel advisors	1.73M	2.42%	$4.05M
Tang capital management	1.55M	2.15%	$2.34M
D. e. shaw	1.48M	2.07%	$3.47M
Two sigma advisers, lp	1.46M	2.03%	$2.21M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mayo clinic	187.14K	25.27%	$765.41K
Tybourne capital management (hk)	961.49K	4.69%	$1.45M
5am venture management	3.95M	2.56%	$9.24M
Pfizer	953.83K	0.84%	$2.00M
Peapod lane capital	366.87K	0.68%	$834.58K
Decheng capital	1.32M	0.47%	$3.10M
Opaleye management	1.41M	0.44%	$3.31M
Almitas capital	610.07K	0.32%	$1.43M
Stonepine capital management	269.10K	0.25%	$629.69K
Anfield capital management	274.52K	0.18%	$642.37K

Top Buyers

Holder	Shares	% Assets	Change
Two sigma investments, lp	2.96M	0.01%	1.49M
Balyasny asset management	970.86K	0.00%	970.86K
Qube research	637.12K	0.00%	619.64K
Millennium management	1.29M	0.00%	616.69K
Susquehanna group, llp	571.26K	0.00%	560.91K

Top Sellers

Holder	Shares	% Assets	Change
Matrix capital management company, lp	-	-	-13.96M
Eventide asset management	-	-	-4.48M
T. rowe price investment management	-	-	-1.33M
Bioimpact capital	-	-	-1.11M
Integral health asset management	-	-	-1.05M

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	304.47K	0.00%	304.47K	$712.46K
Hudson bay capital management lp	117.13K	0.00%	117.13K	$274.08K
Simplex trading	98.55K	0.00%	98.55K	$230.62M
Norges bank	71.53K	-	71.53K	$292.55K
Omers administration	47.70K	0.00%	47.70K	$111.62K

Sold Out

Holder	Change
Caitong asset management	-1.00
Gamma investing	-2.00
True wealth design	-9.00
Advisor group	-10.00
Farther finance advisors	-10.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	34	-60.00%	9,201,108	-77.33%	12	0.41%	18	-51.35%	7	-75.00%
Dec 31, 2025	51	-49.00%	21,959,982	-58.38%	30	0.57%	19	-53.66%	20	-39.39%
Sep 30, 2025	95	-13.64%	52,043,002	0.86%	72	1.41%	41	-24.07%	28	-31.71%
Jun 30, 2025	115	-12.21%	55,620,773	31.52%	77	2.22%	58	-1.69%	42	-14.29%
Mar 31, 2025	134	-8.22%	58,450,755	-9.27%	81	0.99%	60	-34.07%	49	63.33%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	2.83M	3.96%	-2.12M
Vanguard Total Stock Mkt Idx Inv	1.89M	2.66%	196.42K
Vanguard US Total Market Shares ETF	1.89M	2.64%	-
Eventide Gilead N	1.64M	2.30%	-1.94M
Fidelity Growth Compy Commingled Pl O	1.16M	1.63%	-
FIAM Small Cap Core CIT Cl B	886.80K	1.25%	11.50K
Fidelity Growth Compy Commingled Pl S	881.46K	1.24%	-280.77K
FIAM Small Cap Core Composite	866.20K	1.22%	289.81K
Franklin Biotechnology Discv A(acc)USD	759.26K	1.10%	759.26K
Fidelity Small Cap Growth	734.93K	1.03%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 09, 2026	Bruns Ingmar	Chief Medical Officer	Sell	$801.62
Feb 06, 2026	Bruns Ingmar	Chief Medical Officer	Sell	$7.20K
Feb 09, 2026	Vultaggio Vincent	PAO and PFO	Sell	$8.09K
Feb 06, 2026	Vultaggio Vincent	PAO and PFO	Sell	$72.77K
Feb 10, 2026	Vultaggio Vincent	PAO and PFO	Sell	$16.70K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	-
2026 Q1	-	9
2025 Q4	1	1
2025 Q3	-	-
2025 Q2	1	-

ZNTL Ownership FAQ

Who Owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals shareholders are primarily institutional investors at 12.84%, followed by 22.44% insiders and 64.72% retail investors. The average institutional ownership in Zentalis Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Zentalis Pharmaceuticals falls below.

Who owns the most shares of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s largest shareholders are Blackrock (4.82M shares, 6.80%), 5am venture management (3.95M shares, 5.51%), and Two sigma investments, lp (2.96M shares, 4.13%). Together, they hold 16.43% of Zentalis Pharmaceuticals’s total shares outstanding.

Does Blackrock own Zentalis Pharmaceuticals?

Yes, BlackRock owns 6.80% of Zentalis Pharmaceuticals, totaling 4.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.71M$. In the last quarter, BlackRock increased its holdings by 172.79K shares, a 3.72% change.

Who is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Mayo clinic is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 25.27% of its assets in 187.14K Zentalis Pharmaceuticals shares, valued at 765.42K$.

Who is the top mutual fund holder of Zentalis Pharmaceuticals shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Zentalis Pharmaceuticals shares, with 3.96% of its total shares outstanding invested in 2.83M Zentalis Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools